We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Life Sciences

  • November 15, 2018

    Pharma Cos. Must Hand Over Generic Restasis Plans In MDL

    A federal judge Wednesday denied three pharmaceutical companies' move to quash subpoenas for information on their plans to make generic substitutes of Allergan’s drug Restasis in multidistrict litigation over its alleged efforts to delay the generic versions’ launch, saying in-house counsel can view the data without compromising confidentiality.

  • November 15, 2018

    Judge Won't Quash AGs’ Subpoenas In Generic Pricing MDL

    The New York and Connecticut attorneys general can keep sending subpoenas to drugmakers as part of their broader investigations into generic-drug price-fixing, a Pennsylvania federal judge ruled Wednesday, despite the drug companies’ concern the investigations were circumventing the discovery process for a sprawling multidistrict litigation.

  • November 15, 2018

    Deals Rumor Mill: Centrexion, Dayco, JD Group

    Centrexion Therapeutics Corp. has reportedly decided to postpone its plans to go public, Apollo Global Management and Gores Group have lobbed bids for engine parts maker Dayco Products, and JD Group is selling FTLife Insurance Co Ltd.

  • November 15, 2018

    Insys Sales VP To Plead Guilty In Opioid Kickback Case

    A major player in an alleged conspiracy to bribe doctors to prescribe fentanyl-based drugs from the company Insys Therapeutics is prepared to plead guilty, prosecutors said Wednesday in a filing in Boston federal court.

  • November 14, 2018

    J&J Should Pay For Talc Devotee's Death, SC Jury Hears

    Johnson & Johnson should pay tens of millions of dollars in recompense for the life of a South Carolina lawyer who succumbed to mesothelioma at 30 after using talcum powder from birth, her husband's lawyers told a jury Wednesday at the close of a retrial in the case.

  • November 14, 2018

    9th Circ. Judge Doubts Bio-Rad Appeal Of Ex-GC's $11M Win

    A Ninth Circuit judge appeared skeptical Wednesday of Bio-Rad Laboratories Inc.'s arguments in favor of overturning an $11 million whistleblower judgment against the company, repeatedly questioning its counsel during a hearing on how an erroneous jury instruction would change the outcome of the verdict.

  • November 14, 2018

    Gibson Dunn Bows Out Of Pharma RICO Suit Amid DQ Bid

    Gibson Dunn & Crutcher LLP has withdrawn as counsel for Heritage Pharmaceuticals Inc. in the company’s Racketeer Influenced and Corrupt Organizations Act suit against two former executives amid their pending motions to disqualify the firm over its prior ties to them, according to a letter sent by co-counsel to a New Jersey federal judge.

  • November 14, 2018

    Pfizer Debuts Biosimilar Of Amgen, Janssen Meds

    Pfizer Inc. on Wednesday announced the launch of a sharply discounted biosimilar version of Amgen Inc.’s Epogen and Janssen Pharmaceuticals Inc.’s Procrit, capping hard-fought development efforts marked by approval setbacks and ongoing patent litigation at the Federal Circuit.

  • November 14, 2018

    J&J Staves Off Asbestos Baby Powder Suit In Calif. Jury Win

    A California state jury found Wednesday that although Johnson & Johnson's baby powder contained asbestos and a manufacturing defect, it was not a substantial factor in causing a woman's malignant mesothelioma, ruling in favor of the pharmaceutical giant.

  • November 14, 2018

    FTC Shuts Down 1-800 Contacts Online Ad Compacts

    The Federal Trade Commission has ordered an end to a set of marketing agreements between 1-800 Contacts Inc. and its competitors that hurt competition in advertising through online search engines, the agency announced Wednesday.

  • November 14, 2018

    Fed Circ. Won't Stay Immunity Ruling For Allergan's Appeal

    The Federal Circuit has said it wouldn't stay its ruling that sovereign immunity doesn't apply in inter partes reviews while Allergan PLC and the St. Regis Mohawk Tribe appeal to the U.S. Supreme Court.

  • November 14, 2018

    Bio-Rad Wins $24M Jury Verdict In 10X Genomics Patent Suit

    A Delaware federal judge on Wednesday ordered 10X Genomics Inc. to pay nearly $24 million to Bio-Rad Laboratories Inc. and the University of Chicago after a jury found that it infringed a droplet-based method of manipulating DNA.

  • November 14, 2018

    Pa. Panel Urged To Revive Risperdal Breast-Growth Case

    A Philadelphia judge’s mid-trial decision axing claims against a Johnson & Johnson unit over breast growth allegedly linked to the antipsychotic medication Risperdal came under fire Wednesday as a state appeals court heard arguments that the case had been improperly dismissed for lack of scientific proof.

  • November 14, 2018

    Ranbaxy Consumers Denied Cert. In Drug Contamination Suit

    A New Jersey federal judge Wednesday denied class certification in a suit claiming Ranbaxy Pharmaceuticals Inc. distributed pills that might have contained glass, saying there was not enough data to identify who got pills from the potentially affected batches.

  • November 14, 2018

    Aveo CFO Testifies He Had Support For Disclosure Decisions

    Lawyers, board members and company officials all signed off on a decision by Aveo Pharmaceuticals to not tell investors about a recommendation for a new clinical trial, Aveo's former chief financial officer testified Wednesday as the defendant in a civil securities fraud case in Massachusetts federal court.

  • November 14, 2018

    Ropes & Gray Steers Medical Device Co.'s $56M IPO

    Venture-backed medical device company Vapotherm Inc. raised $56 million through an initial public offering that priced at the low end of its range late on Tuesday, represented by Ropes & Gray LLP while Latham & Watkins LLP advised the underwriters.

  • November 14, 2018

    Allergan Cuts A Few State Claims In Restasis MDL

    Health benefits providers that refunded members for the cost of Allergan’s dry-eye medication Restasis will be able to move forward on the majority of the state law claims the drugmaker wanted thrown out, a New York federal judge overseeing multidistrict antitrust litigation has ruled.

  • November 13, 2018

    10 Firms Vie For Lead Counsel In Opko Health Fraud Row

    As many as 10 law firms filed competing motions Tuesday urging a New Jersey federal court to appoint them as lead counsel and their respective clients as lead plaintiffs in a proposed class action against Opko Health Inc. over its alleged role in a pump-and-dump scheme that ultimately dealt a financial blow to investors.

  • November 13, 2018

    Express Scripts, Pharmacy Drama Ends With Last-Minute Deal

    On the first day of trial for a whirlwind breach of contract case between HM Compounding Services LLC and Express Scripts Inc. that has involved attorneys running for the door and significant discovery misconduct, the outstanding claims quickly wrapped up and the parties told a Missouri federal judge Tuesday that they had settled the case.

  • November 13, 2018

    Gottlieb Says FDA Acted Slowly On Opioids

    The head of the U.S. Food and Drug Administration on Tuesday said that the agency in the past had been too slow to act on the opioid crisis and it now plans to look into developing guidelines for prescribing the drugs.

Expert Analysis

  • Q&A

    A Chat With Bryan Cave Innovation Chief Katie DeBord

    Katie DeBord

    In this monthly series, Amanda Brady of Major Lindsey & Africa interviews management from top law firms about the increasingly competitive business environment. Here we feature Katie DeBord, chief innovation officer at Bryan Cave Leighton Paisner LLP.

  • FDA Streamlines 510(k) Process, As Courts Reconsider It

    Caitlin McHugh

    The U.S. Food and Drug Administration is expediting the Section 510(k) approval process for Class II medical devices, while courts are accepting the argument that 510(k) approval signifies safety and effectiveness — with implications for punitive damages awards, say Caitlin McHugh and Matthew Smith of Drinker Biddle & Reath LLP.

  • When A Patent Disclosure Is Not A Disclosure

    Martin Pavane

    ​The Federal Circuit has explained that patent descriptions do not require any particular form of disclosure.​ ​However, the court's recent decision in ​FWP IP v. Biogen point​s​ to a heightened scrutiny of descriptions when an applicant amends or adds new claims to cover a competitor’s activities, say Martin Pavane and Darren Mogil of Cozen O’Connor.

  • Simple Secrets For Improving Your CLE

    Daniel Karon

    With few cases going to trial, many attorneys keep their oral-presentation skills sharp by teaching continuing legal education programs. To avoid giving a CLE that falls flat and damages your reputation, you must fashion a thoughtful message, control its presentation, and nail the beginning and ending, says Daniel Karon of Karon LLC.

  • It’s Time For Law Firms To Start Talking About Gen Z

    Eliza Stoker

    Since the oldest members of Generation Z aren’t even finished with law school yet, law firm management is in a unique position to prepare for their entrance into the legal workforce, says Eliza Stoker of Major Lindsey & Africa.

  • Should Juries Try To Predict FDA Drug Labeling Decisions?

    Alan Klein

    The U.S. Supreme Court's review of Merck v. Albrecht promises to shape the way decisions of regulatory agencies — such as the U.S. Food and Drug Administration’s rejection of a drug manufacturer’s proposed label warning — can be interpreted by juries, say Alan Klein and Matthew Decker at Duane Morris LLP.

  • A Post-Election Survey Of The Health Care Ecosystem

    Andrew Bab

    Health care featured prominently in the 2018 midterm election campaign. Here, attorneys with Debevoise & Plimpton LLP offer thoughts on what the election results and a divided Congress mean for different sectors of the health care industry.

  • Pharmaceutical Warnings: A Changing Landscape

    Chris Essig

    Pharmaceutical warnings and the way they are regulated and litigated are evolving. Brand-name manufacturers face failure-to-warn suits for generic versions of their products, while generic companies may soon have to update warnings on drugs for which there are no longer brand-name versions, say Chris Essig and Schuyler Ferguson of Winston & Strawn LLP.

  • What To Expect From New Democratic Investigation Efforts

    Reginald Brown

    The new Democratic House majority is expected to direct much of its attention to executive branch oversight and accountability. Companies and their legal counsel should be prepared for a dramatically changed collateral environment as investigations cover a wide range of topics, say attorneys at WilmerHale.

  • Q&A

    Back To School: Yale's Linda Greenhouse Talks Journalism

    Linda Greenhouse

    In this series featuring law school luminaries, Yale Law School lecturer and Pulitzer Prize-winning reporter Linda Greenhouse discusses her coverage of the U.S. Supreme Court, the conservatives' long game and trends in journalism.